Boehringer Ingelheim Appoints Brian Hilberdink as President of Human Pharma to Drive Growth

On February 20, Boehringer Ingelheim announced the appointment of Brian Hilberdink as the new President of its Human Pharma division in the United States. This strategic move comes as the company seeks to expand its pipeline and accelerate the launch of several innovative drugs.

Brian Hilberdink brings over 25 years of experience in the pharmaceutical industry, recognized for enhancing industry influence and driving performance. He has held key positions in global marketing, integrated management, and U.S. commercialization, successfully leading the launch of multiple blockbuster drugs and biologics for rare diseases.

Before joining Boehringer Ingelheim, Hilberdink served as Executive Vice President at LEO Pharma, where he was responsible for North America and played a crucial role in driving the company’s global growth. His prior experience at Novo Nordisk further solidified his reputation, where he was instrumental in launching several significant products in the obesity and diabetes sectors.

Jean-Michel Boers, President and CEO of Boehringer Ingelheim USA, commented, “Brian’s extensive commercialization experience with blockbuster drugs and rare disease biologics makes him a perfect addition to our leadership team as we plan for the future. We look forward to transforming the next decade for the patients we serve under his guidance.”

Expressing his enthusiasm, Hilberdink stated, “I am excited to join Boehringer Ingelheim at such a pivotal time as the company embarks on a new chapter of growth and innovation. Together, we can continue the legacy of Boehringer Ingelheim, positively impacting the lives of generations and making a meaningful difference for patients now and in the future.”

This appointment is expected to play a critical role in fostering a strong company culture and delivering significant impacts for patients, as Boehringer Ingelheim looks to enhance its position in the competitive pharmaceutical landscape.